Literature DB >> 28610844

Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.

Janet L Oblinger1, Sarah S Burns1, Jie Huang1, Li Pan2, Yulin Ren2, Rulong Shen3, A Douglas Kinghorn2, D Bradley Welling4, Long-Sheng Chang5.   

Abstract

Meningiomas frequently display activation of the PI3K/AKT/mTOR pathway, leading to elevated levels of phospho-eukaryotic translation initiation factor 4E binding proteins, which enhances protein synthesis; however, it is not known whether inhibition of protein translation is an effective treatment option for meningiomas. We found that human meningiomas expressed high levels of the three components of the eukaryotic initiation factor 4F (eIF4F) translation initiation complex, eIF4A, eIF4E, and eIF4G. The expression of eIF4A and eIF4E was important in sustaining the growth of NF2-deficient benign meningioma Ben-Men-1 cells, as shRNA-mediated knockdown of these proteins strongly reduced cell proliferation. Among a series of 23 natural compounds evaluated, silvestrol, which inhibits eIF4A, was identified as being the most growth inhibitory in both primary meningioma and Ben-Men-1 cells. Silvestrol treatment of meningioma cells prominently induced G2/M arrest. Consistently, silvestrol significantly decreased the amounts of cyclins D1, E1, A, and B, PCNA, and Aurora A. In addition, total and phosphorylated AKT, ERK, and FAK, which have been shown to be important drivers for meningioma cell proliferation, were markedly lower in silvestrol-treated Ben-Men-1 cells. Our findings suggest that inhibiting protein translation could be a potential treatment for meningiomas.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Meningioma; Merlin; Neurofibromatosis type 2 (NF2); Protein translation; Silvestrol; eIF4A; eIF4E; eIF4F; eIF4G

Mesh:

Substances:

Year:  2017        PMID: 28610844      PMCID: PMC5723558          DOI: 10.1016/j.expneurol.2017.06.015

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  57 in total

1.  A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.

Authors:  T Fahrig; I Gerlach; E Horváth
Journal:  Mol Pharmacol       Date:  2005-02-16       Impact factor: 4.436

2.  Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma.

Authors:  B D Li; L Liu; M Dawson; A De Benedetti
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

3.  Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon.

Authors:  H J Berkel; E A Turbat-Herrera; R Shi; A de Benedetti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-06       Impact factor: 4.254

4.  Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.

Authors:  D L Sorrells; C Meschonat; D Black; B D Li
Journal:  J Surg Res       Date:  1999-07       Impact factor: 2.192

5.  Novel flavaglines displaying improved cytotoxicity.

Authors:  Frédéric Thuaud; Nigel Ribeiro; Christian Gaiddon; Thierry Cresteil; Laurent Désaubry
Journal:  J Med Chem       Date:  2010-12-13       Impact factor: 7.446

6.  Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.

Authors:  T Ohse; S Ohba; T Yamamoto; T Koyano; K Umezawa
Journal:  J Nat Prod       Date:  1996-07       Impact factor: 4.050

7.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

8.  Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.

Authors:  Sylwia Ammoun; Christine Flaiz; Natalia Ristic; Jennifer Schuldt; C Oliver Hanemann
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

9.  Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels.

Authors:  I B Rosenwald; R Kaspar; D Rousseau; L Gehrke; P Leboulch; J J Chen; E V Schmidt; N Sonenberg; I M London
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

Review 10.  EANO guidelines for the diagnosis and treatment of meningiomas.

Authors:  Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller
Journal:  Lancet Oncol       Date:  2016-08-30       Impact factor: 41.316

View more
  13 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

Review 2.  Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.

Authors:  Ipsita Pal; Maryam Safari; Marko Jovanovic; Susan E Bates; Changchun Deng
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

3.  Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Authors:  Long-Sheng Chang; Janet L Oblinger; Sarah S Burns; Jie Huang; Larry W Anderson; Melinda G Hollingshead; Rulong Shen; Li Pan; Garima Agarwal; Yulin Ren; Ryan D Roberts; Barry R O'Keefe; A Douglas Kinghorn; Jerry M Collins
Journal:  Mol Cancer Ther       Date:  2019-12-17       Impact factor: 6.261

4.  Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity.

Authors:  Stacey L Lehman; Theresa Wechsler; Kayla Schwartz; Lauren E Brown; John A Porco; William G Devine; Jerry Pelletier; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Ther       Date:  2022-09-06       Impact factor: 6.009

Review 5.  Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species.

Authors:  Garima Agarwal; Long-Sheng Chang; Djaja Doel Soejarto; A Douglas Kinghorn
Journal:  Planta Med       Date:  2021-03-30       Impact factor: 3.007

6.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  Leslie N Aldrich; Joanna E Burdette; Esperanza Carcache de Blanco; Christopher C Coss; Alessandra S Eustaquio; James R Fuchs; A Douglas Kinghorn; Amanda MacFarlane; Brittney K Mize; Nicholas H Oberlies; Jimmy Orjala; Cedric J Pearce; Mitch A Phelps; Liva Harinantenaina Rakotondraibe; Yulin Ren; Djaja Doel Soejarto; Brent R Stockwell; Jack C Yalowich; Xiaoli Zhang
Journal:  J Nat Prod       Date:  2022-02-25       Impact factor: 4.803

7.  Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1.

Authors:  Yang Zhao; Tiantian Li; Shuaiwei Tian; Wei Meng; Yi Sui; Jian Yang; Baocheng Wang; Zhuangzhuang Liang; Heng Zhao; Yipeng Han; Yujie Tang; Lei Zhang; Jie Ma
Journal:  Cancer Manag Res       Date:  2020-12-03       Impact factor: 3.989

Review 8.  Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Mahshad Kalantari; Reza Mohammadinejad; Tahereh Javaheri; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

Review 9.  Translating from cancer to the brain: regulation of protein synthesis by eIF4F.

Authors:  Ilona R Kats; Eric Klann
Journal:  Learn Mem       Date:  2019-08-15       Impact factor: 2.460

Review 10.  Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments.

Authors:  Anusha Amaravathi; Janet L Oblinger; D Bradley Welling; A Douglas Kinghorn; Long-Sheng Chang
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.